Lilly’s Alzheimer’s efforts depend on newer, better biomarkers and diagnostics

The pharma giant’s R&D in Alzheimer’s didn’t end with last year’s Kisunla approval, and diagnostics could define where the company goes next.

By Michael Gibney • Sept. 23, 2025

3 FDA approval firsts that could be around the corner

Several market-altering decisions are on the agency’s docket for the rest of 2025.

By Meagan Parrish • Sept. 19, 2025

Explore the Trendline➔

Oncology R&D

Cancer research remains a prime focus for the industry and often leads to pharma’s most impactful breakthroughs.   

By PharmaVoice staff

How pharma can play a role in the $1 trillion healthcare reinvention

A report from PwC takes a long-term approach to the shifts in healthcare and finds that efficiency in R&D and adaptable business models will define the drugmaker of the future.

By Michael Gibney • Sept. 18, 2025

AI agents are coming to pharma. Here’s what it means for clinical trials.

The high-tech helpers could autonomously navigate tedious tasks — but have to be carefully implemented.

By Kelly Bilodeau • Sept. 17, 2025

Biotech’s VC slowdown forces young drugmakers to adapt in the ‘valley of death’

Amid the sector’s long winter, startups are shifting gears to extend their cash runways.

By Michael Gibney • Sept. 17, 2025

Moderna and BioNTech pioneered mRNA vaccines. But who will make a mark in therapeutics?

While mRNA changed the game in vaccines, leveraging the technology to develop treatments has been trickier to navigate.

By Kelly Bilodeau • Sept. 15, 2025

4 years from clinic to approval — Precigen’s ‘unprecedented’ FDA nod and what comes next

The company scored the first-ever approval to treat a potentially deadly infection leveraging its gene therapy platform.

By Meagan Parrish • Sept. 12, 2025

Ozempic for cancer? Signs point to potential benefits of GLP-1s in oncology.

Growing research suggests various ways weight loss drugs could have an impact in cancer care.

By Michael Gibney • Sept. 11, 2025

A new class of sleep drugs draws Wall Street’s attention

Clinical trial data presented this weekend show drugs from Takeda, Alkermes and Eisai significantly helped people with narcolepsy, heralding a new era of sleep medicine.

By Jacob Bell • Sept. 10, 2025

Pharma’s new boomtown? Why drugmakers are setting up shop in a small Swiss city.

While the EU and UK attempt to lure scientists with new financial incentives, Basel’s stable economy and emphasis on science remains a draw.

By Alexandra Pecci • Sept. 10, 2025

Can new Alzheimer’s tests help clear the way for the next generation of therapies?

A tau-related blood test could offer more insight in early-disease pathology to the complicated Alzheimer’s disease space.

By Michael Gibney • Sept. 9, 2025

Inside pharma’s race to deliver new treatments for dwarfism

By targeting the underlying genetic mutation that drives the condition, researchers hope to increase height and address debilitating complications.

By Kelly Bilodeau • Sept. 8, 2025

International appeal: Europe and UK lure US scientists with financial incentives

With slashed budgets and decimated research programs, American scientists are increasingly looking for career opportunities abroad.

By Alexandra Pecci • Sept. 4, 2025

How AI advances will shape the drugmaker of the future

An AI revolution is taking place, and leaders from tech to Big Pharma are forecasting what drugmakers of the future will look like.

By Michael Gibney • Sept. 2, 2025

How a SpaceX mission could speed drug discoveries on Earth

Research enabled by blasting off into space could lead to better treatments for diseases such as ALS and Parkinson’s.

By Kelly Bilodeau • Aug. 28, 2025

A brewing GLP-1 showdown, from Big Pharma pills to a biotech implant

Newcomers looking for a way into the obesity space are developing unique methods to snag market share.

By Amy Baxter • Aug. 27, 2025

AbbVie dives back into the neuro pool with a $1.2B psychedelics play

Following a major clinical failure last year, AbbVie’s purchase of a psychedelic depression treatment has the potential to revive a touch-and-go market.

By Michael Gibney • Aug. 26, 2025

And just like that... pharma’s breakups reveal pain points in cancer R&D

Biotech tie-ups with Gilead, Genetech and Ipsen that have recently been let go.

By Meagan Parrish • Aug. 22, 2025

In cell therapy, cost is a hot issue. The industry might need a cold solution.

The logistical linchpin of cryopreservation could make a challenging space more accessible.

By Michael Gibney • Aug. 19, 2025

Merck KGaA ventures into new territory in the US

How the president of EMD Serono, Merck KGaA, Darmstadt, Germany’s U.S. arm, is leading the charge to “double down” on new innovation.

By Alexandra Pecci • Aug. 15, 2025

With scrapped mRNA funding, a vaccine maker finds a silver lining

While mRNA is suffering the brunt of the MAHA movement with $500 million in funding cuts, other vaccine makers could fill some of that void.

By Michael Gibney • Aug. 14, 2025

3 ways the GLP-1 market has changed shape this year

Novo Nordisk and Eli Lilly’s quarterly earnings revealed shifting dynamics in the lucrative obesity space.

By Amy Baxter • Aug. 12, 2025

Are stem cell therapies ready for pharma’s prime time?

Stem cell therapies are thriving on the fringes of healthcare — but science-backed treatments are also poised to make an impact in pharma R&D.

By Kelly Bilodeau • Aug. 11, 2025

As gene therapies falter on the market, this biopharma is aiming to defy the odds

After a strong launch for its cancer gene therapy, Ferring Pharmaceuticals is setting the stage for long-term growth.

By Meagan Parrish • Aug. 8, 2025

Inside AstraZeneca’s long-game strategy in lung cancer

New long-term results for Tagrisso in EGFR-mutated non-small cell lung cancer showcase a precision approach the company has honed for decades.

By Michael Gibney • Aug. 7, 2025